Overview
- Eli Lilly, which reported results Wednesday, beat expectations with about $23 billion in second‑quarter revenue and $8.38 in adjusted earnings per share.
- Sales of injectable GLP‑1 drugs drove the beat, with Mounjaro generating roughly $9.94 billion worldwide and Zepbound posting about $4.93 billion in U.S. revenue for the quarter.
- Lilly said rising prescription volumes powered growth even as realized prices fell, with international revenue jumping sharply after Mounjaro was added to China’s reimbursement list and U.S. Medicare expanded obesity coverage.
- The company reported $98 million in Foundayo pill sales in its first quarter on the market and disclosed roughly $3.03 per‑share acquisition‑related charges while completing multiple deals and agreeing to buy AtaiBeckley for about $2.8 billion upfront.
- Lilly is channeling GLP‑1 cash flow into capacity and technology, including a $4.5 billion commitment to Indiana manufacturing and a reported up‑to‑$1 billion joint AI lab with Nvidia, as it advances next‑generation candidates such as retatrutide.